Background:Many South African peripheral medical centres lack direct access to CT scans or neurosurgery. The Glasgow Coma Scale (GCS), used with or without other findings, remains widely utilised in traumatic brain injury (TBI) assessments with lack of standardisation between centres. There is limited data from South Africa (SA) correlating GCS scores to CT imaging in TBI. Objectives:This study aimed to assess CT findings at various GCS levels to determine whether GCS was a reliable indicator for imaging and referral. Method:A retrospective review of 385 patients categorised with mild, moderate or severe TBI was performed. The initial non-sedated post-resuscitation GCS score and initial CT brain findings were compared using the chi-square and Fisher's exact tests. Results:Increased intracranial pressure and subdural haemorrhage occurred in 41.7% and 53.7% of patients with GCS 9-12, respectively, and 30.5% and 41.4% of patients with GCS 13-15, respectively. The highest incidence of depressed skull fractures (51.3%; 95% confidence interval [CI], 43.2-59.3%; p < 0.001) and pneumocephalus (25.6%; 95% CI, 42.2-56.4; p < 0.001) were reported in the CGS 13-15 category. Neurosurgical intervention was required in 83.2% and 73.0% of patients with GCS scores of 9-12 and 13-15, respectively. Conclusion:The severe category of GCS predicts imaging and neurosurgery requirements while the mild to moderate categories underpredict the need for patient referral. Contribution:This study provides rationale for the development of a local, standardised assessment tool to guide referral of TBI patients for imaging in resource-limited settings.
Abstract The May Measurement Month (MMM) campaign, conducted in South Africa in 2023 aimed to raise awareness of raised blood pressure (BP). Adults aged ≥18 years were recruited through convenience sampling at university campuses, community centres, schools, sport complexes, public parks, shopping centres, hospitals, and through household visits. Three seated BP readings were taken on each participant, and a questionnaire collected information on demographics, lifestyle factors, and comorbidities. Hypertension was defined as a systolic BP ≥140mmHg and/or diastolic BP ≥90mmHg and/or already receiving BP-lowering medication. Controlled BP was defined as being on BP-lowering medication with a BP <140/90mmHg. Multiple imputation was used to estimate missing BP readings. In total, 6,653 were screened, with a mean age of 38.8 years, the majority of whom were females (56.3%). Of all participants, 1,010 (15.2%) reported never having had a BP measured before, 2,500 (37.6%) had hypertension, of whom 1,170 (46.8%) were aware, and 1,098 (43.9%) were on antihypertensive medication. Of those on antihypertensive medication, only 633 (57.7%) had controlled BP, and of all participants with hypertension, only 25.3% had controlled BP. The MMM campaign in South Africa identified a substantial number of participants with untreated or inadequately treated hypertension. The high prevalence of hypertension, despite the young adult age, together with the high proportions of individuals unaware of their hypertension and with uncontrolled BP highlight the importance of hypertension screening and awareness campaigns, and more rigorous management of hypertension, especially among young adults.
BACKGROUND: Kaposi sarcoma herpes virus (KSHV)-associated inflammatory cytokine syndrome (KICS) is defined by clinical, laboratory, and radiographic findings and KSHV viremia. Whether the presenting clinical symptoms of KICS have prognostic value in patients with HIV-associated Kaposi sarcoma (HIV-KS) initiating therapy is unknown. SETTING: Two prospective clinical trials were conducted among participants with mild-to-moderate (A5264/AMC067) and advanced (A5263/AMC066) HIV-KS in low-income and middle-income countries. All participants received antiretroviral therapy, and chemotherapy was given according to the randomly assigned treatment arm. METHODS: We developed a Kaposi sarcoma clinical symptom score (KSCS score), derived from the previously described KICS definition to determine whether the score could inform prognosis. The score ranging from 0 to 3 was based on increasing severity of clinical manifestations. We evaluated the impact of baseline KSCS score on progression-free and overall survival using Cox proportional hazard regression. RESULTS: Of 190 participants in A5264/AMC067 and 329 in A5263/AMC066, 150 (78.9%) and 239 (72.6%) had KSCS score ≥1 and 15 (7.9%) and 95 (28.9%) had KSCS score 3, respectively. Independent of the treatment arm, participants with KSCS score 3 had a higher risk of death (A5264/AMC067: adjusted hazard ratio (aHR) = 9.17; 95% CI: 3.60 to 23.41; A5263/AMC066: aHR = 2.99; 95% CI: 1.69 to 5.28) and shorter progression-free survival (A5264/AMC067: aHR = 2.36 95% CI: 1.26 to 4.43; A5263/AMC066: aHR = 2.31; 95% CI: 1.23 to 3.60) compared with those with KSCS score ≤2. CONCLUSIONS: KSCS score symptoms are common, especially in advanced HIV-KS. KSCS score 3 is associated with higher risk of progressive KS disease or death, despite treatment with antiretrovirals and chemotherapy. This population may benefit from improved diagnostic and management options.
BACKGROUND:Data on predictors of treatment failure in children starting antiretroviral therapy (ART) are limited, particularly on dolutegravir-based regimens (DTG). METHODS:ODYSSEY demonstrated superior efficacy of DTG versus standard-of-care (SOC). We assessed predictors at ART initiation of treatment failure by 96 weeks. RESULTS:Three hundred and eighty-one children started first-line ART (82% African). At ART-initiation, median age was 10.5 years (IQR: 6.5, 14.0, 67 < 3 years), CD4% 20% (IQR: 12, 28), BMI-for-age Z-score -.58 (IQR:-1.48, +.25). One hundred and eighty-nine children started DTG, 192 started SOC (91% ≥3 years started efavirenz; 79% <3 years started lopinavir). Seventy-five children experienced treatment failure (24 DTG, 51 SOC). Failure risk was lower on DTG than SOC (hazard ratio [HR] = 0.47, 95% CI: 0.29-0.77, P = .002). Lower BMI-for-age Z-score (HR = 0.82 for each unit gain, 95% CI: 0.70-0.96, P = .01) and being at an African site (HR = 2.09, 95% CI: 0.82-5.31, P = .09) were associated with higher failure risk. Risk was also higher at younger ages with the steepest increase in the youngest children and increased at lower CD4%, with a stronger CD4% effect at younger ages. At CD4% = 20, HRs relative to age 10 years were 2.40 (95% CI: 1.58-3.65) at age 1 year, 1.30 (95% CI: 1.15-1.48) at age 5 years, and 0.80 (95% CI: 0.72-0.89) at age 18 years. At age 1 year, HRs relative to CD4% = 20 were 1.39 (95% CI: 1.16-1.66) at CD4% = 15, and 0.52 (95% CI: 0.36-0.75) at CD4% = 30; at age 10, corresponding estimates were 1.07 (95% CI: 0.94-1.20) at CD4% = 15, and 0.88 (95% CI: 0.69-1.13) at CD4% = 30. CONCLUSIONS:Young age, low BMI-for-age, and low CD4% at ART initiation predicted higher risk of treatment failure and can guide targeted support.
Introduction Total alloplastic replacement of the temporomandibular joint (TMJ) is a viable treatment option for severe TMJ disorders (TMDs) unresponsive to conservative approaches, as well as for reconstruction of congenital or acquired TMJ defects. However, clinical data on indications, outcomes, complications and long-term effects remain limited, and no global registry currently exists. This study aims to address this gap by establishing an international registry to collect data from patients undergoing total alloplastic TMJ replacement systematically. The registry will document clinical indications and disease progression, explore relationships between treatments, outcomes and quality of life, identify predictors of favourable outcomes and inform future research.Methods and analysis This international, prospective, multicentre, observational registry will enrol approximately 200 patients with TMD requiring total alloplastic TMJ replacement, with follow-up lasting up to 5 years postoperatively. The data collected will include underlying disease, treatment details, functional outcomes, patient-reported outcomes and procedure-related adverse events. The registry will also monitor patients who decline surgery and record their reasons. All treatments will adhere to the standard of care at each participating centre.Ethics and dissemination Ethics approval was obtained from the responsible ethics committee (EC) at each participating site prior to TMJ surgery. All patients will be enrolled following an informed consent process approved by the relevant EC. Study results will be disseminated through peer-reviewed publications.Approving ECs include: Krishnadevaraya College of Dental Sciences and Hospital EC, KCDS/Ethical Comm/54/2022–23; Ethikkommission Nordwest- und Zentralschweiz, 2019–02387; University of Belgrade School of Dental Medicine EC, 36/19; National Videnskabsetisk Komité, 2401881; University of KwaZulu-Natal Biomedical Research EC, BREC/00001592/2020; Etikprövningsmyndigheten, 2019–04477; Ethikkommission Medizinische Hochschule Hannover, 8660_BO_K_2019; Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig, 080/21-lk; Comité de Ética de la Investigación con Medicamentos Hospital Universitario 12 de Octubre, 19/392; Landesärztekammer Rheinland-Pfalz EC, 2025–18012-andere Forschung/nachberatend; Local Ethical Committee at National Medical and Surgical Centre named after NI Pirogoov, LEC meeting 5; Ethikkommission bei der LMU München, 19–589; Komisja Bioetyczna przy Warmińsko-Mazurskiej Izbie Lekarskiej w Olsztynie, 12/2021; De Medisch Ethische Toetsings Commissie Erasmus MC, MEC-2019–0696 and Comissão Nacional de Ética em Pesquisa, 3.825.711.Trial registration number NCT03991728.